Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|January 1, 1998
- Psychiatric Times Vol 15 No 1
- Volume 15
- Issue 1
Alleged Unabomber Puts Psychiatry on Trial
Listen
0:00 / 0:00
Key Takeaways
- Anticipated stigma is framed as inevitable, with others expected to impose value-laden, pathologizing labels and motives.
- Emotional salience centers on epistemic accuracy, not social condemnation, emphasizing frustration with mischaracterization of psychological facts.
For 17 years, claim federal prosecutors, Theodore Kaczynski terrorized the nation with a string of 16 bombings that killed three people and injured 23 more. On trial now for his life, the alleged Unabomber's case will most likely hinge on the expert testimony proffered by a covey of psychiatrists and psychologists scheduled to be called as witnesses as the case unfolds in U.S. District Court in Sacramento, Calif. this month.
Advertisement
"...they are bound to make me out to be a sickie, and to ascribe to me motives of a sordid or 'sick' type....I am not very concerned about the negative value judgments that will be made about me, but it does anger me that the facts of my psychology will be misrepresented. For that reason I have attempted to give here an account of my own personality and its development that will be as accurate as possible."
Articles in this issue
almost 29 years ago
Oregon Suicide Law in Limbo for Nowalmost 29 years ago
January Thawalmost 29 years ago
Association of Gay and Lesbian Psychiatrists (AGLP)almost 29 years ago
Examining Anger in 'Culture-Bound' Syndromesalmost 29 years ago
The Internet and MEDLINEalmost 29 years ago
Psychotherapy for Gay and Lesbian Clientsalmost 29 years ago
Therapist-Patient Race and Sex Matching: Predictors of Treatment DurationAdvertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5